The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

被引：0
|
作者：
Papageorgiou, Sotirios
Kontos, Christos K.
Tsiambalis, Thomas
Vyniou, Athina
Symeonidis, Argiris
Galanopoulos, Athanasios
Kotsianidis, Ioannis
Pappa, Vassiliki
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4252
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group
    Papageorgiou, Sotirios G.
    Vasilatou, Diamantina
    Kontos, Christos K.
    Kotsianidis, Ioannis
    Symeonidis, Argiris
    Galanopoulos, Athanasios G.
    Hatzimichael, Eleftheria
    Megalakaki, Aekaterini
    Poulakidas, Elias
    Diamantopoulos, Panagiotis
    Vassilakopoulos, Theodoros P.
    Zikos, Panagiotis
    Papadaki, Helen
    Mparmparousi, Despoina
    Bouronikou, Eleni
    Panayiotidis, Panayiotis
    Viniou, Nora-Athina
    Pappa, Vassiliki
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (07) : 895 - 901
  • [2] CLINICAL VALUE OF MONOSOMAL KARYOTYPE AND COMPLEX KARYOTYPE AS PROGNOSTIC PARAMETER IN PATIENTS WITH IPSS INTERMEDIATE-2 AND HIGH RISK MYELODYSPLASTIC SYNDROMES TREATED WITH AZACITIDINE
    Song, M. K.
    Chung, J. S.
    Moon, J. H.
    Ahn, J. S.
    Song, I. C.
    Hong, J.
    Lee, G. W.
    Shin, H. J.
    HAEMATOLOGICA, 2014, 99 : 346 - 346
  • [3] Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine
    Itzykson, R.
    Thepot, S.
    Eclache, V.
    Quesnel, B.
    Dreyfus, F.
    Beyne-Rauzy, O.
    Turlure, P.
    Vey, N.
    Recher, C.
    Boehrer, S.
    Gardin, C.
    Ades, L.
    Fenaux, P.
    LEUKEMIA, 2011, 25 (07) : 1207 - 1209
  • [4] Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine
    R Itzykson
    S Thépot
    V Eclache
    B Quesnel
    F Dreyfus
    O Beyne-Rauzy
    P Turlure
    N Vey
    C Recher
    S Boehrer
    C Gardin
    L Adès
    P Fenaux
    Leukemia, 2011, 25 : 1207 - 1209
  • [5] Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome
    Nishihori, Taiga
    Perkins, Janelle
    Mishra, Asmita
    Komrokji, Rami
    Kim, Jongphil
    Kharfan-Dabaja, Mohamed A.
    Perez, Lia
    Lancet, Jeffrey
    Fernandez, Hugo
    List, Alan
    Anasetti, Claudio
    Field, Teresa
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (06) : 776 - 780
  • [6] Prognostic impact of a monosomal Karyotype in high-grade myelodysplastic syndromes treated by Azacytidine
    Saada, Veronique
    HEMATOLOGIE, 2011, 17 (05): : 312 - 313
  • [7] EXPERIENCE WITH 5-AZACITIDINE IN PATIENTS DIAGNOSED BY MYELODYSPLASTIC SYNDROMES OF INTERMEDIATE 2/HIGH RISK
    Llorente Dunia, De Miguel
    Lopez Nuria, Golbano
    Morfa Miguel, Diaz
    Juanis Jaime, Arbeteta
    Sanz Dolores, Morales
    Ramo Alejandro, Vazquez
    Maqueda Cristina, Fernandez
    Garcia Helga, Guillen
    Perez Dolores, Subira
    Martin Sonia, Herrero
    Albiz Blanca, Pinedo
    HAEMATOLOGICA, 2016, 101 : 341 - 341
  • [8] The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine
    Kamiya, Takahiro
    Nakazato, Tomonori
    MEDICAL ONCOLOGY, 2019, 36 (03)
  • [9] The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine
    Takahiro Kamiya
    Tomonori Nakazato
    Medical Oncology, 2019, 36
  • [10] INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
    Ramos, S.
    Santos, M.
    Tenreiro, R.
    Pereira, M.
    Cortesao, E.
    Rito, L.
    Ribeiro, M. L.
    HAEMATOLOGICA, 2015, 100 : 474 - 475
12345